Suppr超能文献

异种雌激素调节精氨酸甲基转移酶的活性。

Xenoestrogens regulate the activity of arginine methyltransferases.

机构信息

Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.

出版信息

Chembiochem. 2011 Jan 24;12(2):323-9. doi: 10.1002/cbic.201000522. Epub 2010 Dec 17.

Abstract

Arginine methylation is a common post-translational modification that has been strongly implicated in transcriptional regulation. The arginine methyltransferases (PRMTs) were first reported as transcriptional coactivators for the estrogen and androgen receptors. Compounds that inhibit these enzymes will provide us with valuable tools for dissecting the roles of these enzymes in cells, and will possibly also have therapeutic applications. In order to identify such inhibitors of the PRMTs, we have previously performed a high-throughput screen using a small molecule library. These compounds were named arginine methyltransferase inhibitors (AMIs). The majority of these inhibitors were polyphenols, and one in particular (AMI-18) shared additional features with a group of known xenoestrogens. We, thus, tested a panel of xenoestrogens and found that a number of them possess the ability to inhibit PRMT activity, in vitro. These inhibitors primarily target CARM1, and include licochalcone A, kepone, benzyl 4-hydroxybenzoate, and tamoxifen. We developed a cell-based reporter system for CARM1 activity, and showed that tamoxifen (IC(50) =30 μM) inhibits this PRMT. The ability of these compounds to regulate the activity of transcriptional coactivators may be an unappreciated mechanism of action for xenoestrogens, and might also explain the efficacy of high-dose tamoxifen treatment on estrogen receptor negative cancers.

摘要

精氨酸甲基化是一种常见的翻译后修饰,它与转录调控密切相关。精氨酸甲基转移酶(PRMTs)最初被报道为雌激素和雄激素受体的转录共激活剂。抑制这些酶的化合物将为我们提供研究这些酶在细胞中作用的有价值的工具,并且可能具有治疗应用。为了鉴定这些 PRMT 的抑制剂,我们之前使用小分子文库进行了高通量筛选。这些化合物被命名为精氨酸甲基转移酶抑制剂(AMIs)。这些抑制剂中的大多数是多酚,其中一种(AMI-18)与一组已知的外源性雌激素具有额外的特征。因此,我们测试了一组外源性雌激素,发现其中许多具有抑制 PRMT 活性的能力,体外。这些抑制剂主要针对 CARM1,包括甘草查尔酮 A、开蓬、对羟基苯甲酸苄酯和他莫昔芬。我们开发了一种用于 CARM1 活性的基于细胞的报告系统,并表明他莫昔芬(IC(50)=30 μM)抑制这种 PRMT。这些化合物调节转录共激活剂活性的能力可能是外源性雌激素作用的一种未被认识的机制,也可能解释高剂量他莫昔芬治疗雌激素受体阴性癌症的疗效。

相似文献

1
Xenoestrogens regulate the activity of arginine methyltransferases.异种雌激素调节精氨酸甲基转移酶的活性。
Chembiochem. 2011 Jan 24;12(2):323-9. doi: 10.1002/cbic.201000522. Epub 2010 Dec 17.
5
A novel arginine methyltransferase inhibitor with cellular activity.一种具有细胞活性的新型精氨酸甲基转移酶抑制剂。
Bioorg Med Chem Lett. 2007 Aug 1;17(15):4150-3. doi: 10.1016/j.bmcl.2007.05.088. Epub 2007 Jun 3.
6
Small Molecule Inhibitors of Protein Arginine Methyltransferases.蛋白质精氨酸甲基转移酶的小分子抑制剂
Expert Opin Investig Drugs. 2016;25(3):335-58. doi: 10.1517/13543784.2016.1144747. Epub 2016 Feb 16.
8
Selective inhibitors of protein methyltransferases.蛋白甲基转移酶选择性抑制剂。
J Med Chem. 2015 Feb 26;58(4):1596-629. doi: 10.1021/jm501234a. Epub 2014 Dec 2.

引用本文的文献

1
The emerging role of CARM1 in cancer.CARM1 在癌症中的新兴作用。
Cell Oncol (Dordr). 2024 Oct;47(5):1503-1522. doi: 10.1007/s13402-024-00943-9. Epub 2024 Apr 15.
2
Anticancer effects of licochalcones: A review of the mechanisms.甘草查耳酮类化合物的抗癌作用:作用机制综述
Front Pharmacol. 2023 Jan 23;14:1074506. doi: 10.3389/fphar.2023.1074506. eCollection 2023.
3
Role of Licochalcone A in Potential Pharmacological Therapy: A Review.甘草查尔酮A在潜在药物治疗中的作用:综述
Front Pharmacol. 2022 May 23;13:878776. doi: 10.3389/fphar.2022.878776. eCollection 2022.
5
CARM1 methylates MED12 to regulate its RNA-binding ability.CARM1使MED12发生甲基化以调节其RNA结合能力。
Life Sci Alliance. 2018 Sep 19;1(5):e201800117. doi: 10.26508/lsa.201800117. eCollection 2018 Oct.

本文引用的文献

10
Enzymatic activity is required for the in vivo functions of CARM1.需要酶活性来实现 CARM1 的体内功能。
J Biol Chem. 2010 Jan 8;285(2):1147-52. doi: 10.1074/jbc.M109.035865. Epub 2009 Nov 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验